---
figid: PMC6590809__pone.0218459.g001
figlink: /pmc/articles/PMC6590809/figure/pone.0218459.g001/
number: F1
caption: 'Primary bile acids are synthesized from cholesterol in the liver, via either
  the classical pathway, which produces CA, or the alternative pathway, which produces
  CDCA, or, in mice only, α- or β-MCA.[, ] Bile acids are conjugated with glycine
  or taurine (predominantly taurine in mice) before being released into the bile.[]
  In the gut, bile acids are deconjugated and metabolized into secondary bile acids
  [, , ] (UDCA is considered a secondary bile acid in humans [] but a primary bile
  acid in mice).[] About 95% of bile acids are reabsorbed from the gut and transported
  back to the liver via the hepatic portal vein, and the remainder are excreted.[,
  , ] The hydrophilicity of the common free and conjugated bile salts decreases in
  the order UDCA > CA > CDCA > DCA) > LCA, and taurine-conjugated > glycine-conjugated
  > free species.[] ASBT inhibition with volixibat blocks the reabsorption of bile
  acids and increases their excretion, stimulating the liver to synthesize more bile
  acids from cholesterol.[–] ASBT: apical sodium-dependent bile acid transporter,
  CA: cholic acid, CDCA: chenodeoxycholic acid, Cyp: cytochrome P450 family, DCA:
  deoxycholic acid, G: glycine, HDCA: hyodeoxycholic acid, LCA: lithocholic acid,
  MCA: muricholic acid, T: taurine, UDCA: ursodeoxycholic acid.'
pmcid: PMC6590809
papertitle: Apical sodium-dependent bile acid transporter inhibition with volixibat
  improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden
  mice.
reftext: Kanita Salic, et al. PLoS One. 2019;14(6):e0218459.
pmc_ranked_result_index: '78375'
pathway_score: 0.7350302
filename: pone.0218459.g001.jpg
figtitle: Apical sodium-dependent bile acid transporter inhibition with volixibat
  improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden
  mice
year: '2019'
organisms:
- Mus musculus
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6590809__pone.0218459.g001.html
  '@type': Dataset
  description: 'Primary bile acids are synthesized from cholesterol in the liver,
    via either the classical pathway, which produces CA, or the alternative pathway,
    which produces CDCA, or, in mice only, α- or β-MCA.[, ] Bile acids are conjugated
    with glycine or taurine (predominantly taurine in mice) before being released
    into the bile.[] In the gut, bile acids are deconjugated and metabolized into
    secondary bile acids [, , ] (UDCA is considered a secondary bile acid in humans
    [] but a primary bile acid in mice).[] About 95% of bile acids are reabsorbed
    from the gut and transported back to the liver via the hepatic portal vein, and
    the remainder are excreted.[, , ] The hydrophilicity of the common free and conjugated
    bile salts decreases in the order UDCA > CA > CDCA > DCA) > LCA, and taurine-conjugated
    > glycine-conjugated > free species.[] ASBT inhibition with volixibat blocks the
    reabsorption of bile acids and increases their excretion, stimulating the liver
    to synthesize more bile acids from cholesterol.[–] ASBT: apical sodium-dependent
    bile acid transporter, CA: cholic acid, CDCA: chenodeoxycholic acid, Cyp: cytochrome
    P450 family, DCA: deoxycholic acid, G: glycine, HDCA: hyodeoxycholic acid, LCA:
    lithocholic acid, MCA: muricholic acid, T: taurine, UDCA: ursodeoxycholic acid.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CYP7A1
  - CYP27A1
  - GUCY2D
  - CYP7B1
  - SLC10A2
  - CYP8B1
  - Cholesterol
  - Ta
  - hydroxycholesterol
  - bile acids
  - CDCA
  - B-MCA
  - UDCA
  - T-CDCA
  - DCA
  - HDCA
genes:
- word: Cyp7a1
  symbol: CYP7A1
  source: hgnc_symbol
  hgnc_symbol: CYP7A1
  entrez: '1581'
- word: Cyp27a1
  symbol: CYP27A1
  source: hgnc_symbol
  hgnc_symbol: CYP27A1
  entrez: '1593'
- word: LCA/UDCA
  symbol: LCA
  source: hgnc_prev_symbol
  hgnc_symbol: GUCY2D
  entrez: '3000'
- word: Cyp7b1
  symbol: CYP7B1
  source: hgnc_symbol
  hgnc_symbol: CYP7B1
  entrez: '9420'
- word: ASBT
  symbol: ASBT
  source: hgnc_prev_symbol
  hgnc_symbol: SLC10A2
  entrez: '6555'
- word: Cyp8b1
  symbol: CYP8B1
  source: hgnc_symbol
  hgnc_symbol: CYP8B1
  entrez: '1582'
chemicals:
- word: Cholesterol
  source: MESH
  identifier: D002784
- word: Ta
  source: MESH
  identifier: D013635
- word: hydroxycholesterol
  source: MESH
  identifier: D006888
- word: bile acids
  source: MESH
  identifier: D001647
- word: CDCA
  source: MESH
  identifier: C081330
- word: B-MCA
  source: MESH
  identifier: C053715
- word: UDCA
  source: MESH
  identifier: C433771
- word: T-CDCA
  source: MESH
  identifier: C081330
- word: DCA
  source: MESH
  identifier: C048628
- word: HDCA
  source: MESH
  identifier: C061217
diseases: []
figid_alias: PMC6590809__F1
redirect_from: /figures/PMC6590809__F1
figtype: Figure
---
